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Abstract 27 
 28 
Affordable next generation sequencing (NGS) technologies for hepatitis C virus (HCV) may 29 
potentially identify both viral genotype and resistance genetic motifs in the era of directly 30 
acting anti-viral (DAA) therapies. This study compared the ability of high-throughput NGS 31 
methods to generate full-length, deep, HCV viral sequence datasets and evaluated their 32 
utility for diagnostics and clinical assessment.NGS methods using (1) unselected HCV RNA 33 
(metagenomic); (2) pre-enrichment of HCV RNA by probe capture and (3) HCV pre-34 
amplification by PCR implemented in four UK centres were compared. Metrics of sequence 35 
coverage and depth, quasispecies diversity and detection of DAA-resistance associated 36 
variants (RAVs), mixed HCV genotype and other co-infections were compared using a panel 37 
of samples of varying viral load, genotype and mixed HCV geno(sub)types. Each NGS method 38 
generated near complete genome sequences from over 90% of samples. Enrichment 39 
methods and PCR pre-amplification generated greater sequence depth and were more 40 
effective for low viral load samples. All NGS methodologies accurately identified mixed HCV 41 
genotype infections. Consensus sequences generated by different NGS methods were 42 
generally concordant and majority RAVs were consistently detected. However, methods 43 
differed in their ability to detect minor populations of RAVs. Metagenomic methods 44 
identified human pegivirus co-infections. NGS provided a rapid, inexpensive method for 45 
generating whole HCV genomes to define infecting genotypes, RAVs, comprehensive viral 46 
strain analysis and quasispecies diversity. Enrichment methods are particularly suited for 47 
high-throughput analysis while providing genotype and information on potential DAA 48 
resistance.  49 
50 
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Introduction  51 
Hepatitis C virus (HCV) chronically infects over 150 million people globally and is associated 52 
with the development of liver fibrosis, cirrhosis, hepatic failure and hepatocellular cancer 53 
(1). Historically, treatment of HCV has been based on interferon-alpha (IFN-α) and ribavirin 54 
(RBV) which are associated with high treatment failure rates and severe side effects. New 55 
all-oral direct acting antivirals (DAAs), with high efficacy rates and an improved safety profile 56 
have recently revolutionised the treatment of HCV. Most recently, oral therapies that target 57 
NS3, NS5A and NS5B HCV proteins have been approved by the Food and Drug 58 
Administration and European Medicines Agency regulatory bodies (2, 3) and used in 59 
combination, these DAAs achieve high sustained virological response (SVR) rates with 60 
minimal side effects (4). HCV is currently classified into seven major genotypes and sixty-61 
seven subtypes (5). At present there is no truly pan-genotypic DAA treatment regimen, with 62 
both drug choice and treatment duration defined by viral genotype. Genotype 3 in particular 63 
appears less susceptible to DAA therapies (6). Therefore, the accurate assignment of viral 64 
genotype and subtype remains an important stratification parameter both in clinical trials of 65 
DAA therapy and in clinical practice.  66 
 67 
Although a minority of patients fail to achieve SVR with all oral combination therapy, failure 68 
more commonly occurs in patients with advanced liver disease, and optimal retreatment 69 
strategies in all patients who fail DAA therapies are currently unclear. Initially it was reported 70 
that treatment failure with combination DAAs was rarely associated with the development 71 
of viral resistant associated variants (RAVs) and therefore the role for the development of 72 
sequencing technologies or phenotypic characterisation to assess RAVs was unclear. 73 
However, with the exception of the NS5B inhibitors, each of the DAAs is known to have a 74 
low genetic barrier for the development of antiviral resistance and naturally occurring HCV 75 
polymorphisms may confer DAA resistance. Currently, pre-screening for RAVs prior to 76 
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treatment is only recommended for the NS3 protease inhibitor simeprevir (7), since the 77 
Q80K mutation that can confer resistance is widely distributed among genotype 1a variants. 78 
However, whilst simeprevir may soon become obsolete in HCV treatment strategies, careful 79 
analysis of viral sequence by independent investigators has revealed that RAVs may emerge 80 
in association with DAA treatment failure even with the high barrier to resistance NS5B 81 
inhibitors (8). The emergence of resistance to DAAs targeting NS5A is clearly documented 82 
and of particular concern as these do not incur a significant fitness cost for replication. They 83 
can persist and transmit in the community (9).  84 
 85 
Currently the assessment of viral genotype commonly uses probe-based assays that target 86 
the highly conserved 5’UTR, whilst the detection of RAVs currently relies upon the targeted 87 
analysis of genomic regions that rely on polymerase chain reaction (PCR) Sanger sequencing; 88 
the application of this method is limited by problems with primer design for highly divergent 89 
HCV genotypes, genome coverage and a restricted and inconsistent ability to detect both 90 
minor populations of RAVs as well as mixed geno(sub)type infections that may be relevant 91 
for treatment response. We therefore developed and compared next generation sequencing 92 
technologies (NGS) for the generation of full length HCV sequences, with the potential to 93 
accurately define HCV geno (sub) type whilst also simultaneously identifying both RAV and 94 
minor variant populations across the entire genome. Whole genome sequencing (WGS) that 95 
could be routinely applied in clinical practice could inform re-treatment strategies and also 96 
provide more detailed sequence data to examine transmission events between individuals 97 
and potentially inform public health intervention strategies. Together, these capabilities 98 
would represent a major advance in the field.  99 
 100 
We evaluated and compared three approaches across four UK laboratories in order to 101 
establish the robustness of pipelines for sequencing HCV RNA from plasma. The simplest, 102 
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“metagenomic” approach obtains data that is unbiased by infecting genotype, with the 103 
potential benefit of detecting additional pathogens but with the substantial disadvantage 104 
that the vast majority of sequence reads obtained are of human origin and are discarded. 105 
“Enrichment” approaches provide an alternative in which HCV sequences are targeted for 106 
capture from metagenomic sequencing libraries using panels of oligonucleotide probes but 107 
at the expense of missing non-targeted pathogens and, potentially, divergent HCV 108 
sequences. Both techniques were compared with an approach in which the HCV genome is 109 
spanned by six overlapping PCR amplicons which are pooled and sequenced to high depth by 110 
NGS.  111 
 112 
In evaluating the effectiveness of metagenomic, enrichment and PCR amplification 113 
approaches to HCV whole-genome sequencing, we compared data generated using a variety 114 
of protocols at different laboratory sites and so explored the reproducibility of aspects of the 115 
sequence data in independent trials, including the generation of accurate consensus 116 
sequences, detection of quasispecies diversity and full sequence coverage of the HCV 117 
genome. The analysis allowed us to define a relationship between sequencing depth and 118 
coverage with RNA viral loads and so predict the expected success rates for clinical samples. 119 
Finally, we explored the reproducibility of recovery of virus sub-populations and minor 120 
variants, using panels of mixed samples and DAA-associated polymorphisms.  121 
 122 
 123 
Methods.  124 
 125 
Samples. A range of plasma samples, assay controls and in vitro transcripts were used to 126 
evaluate NGS methods. These comprised:  127 
 128 
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1) Plasma Samples. Plasma samples from individuals infected with genotypes 1a, 1b, 2, 3 and 129 
4 were obtained from the HCVResearchUK Biobank (http://www.hcvresearchuk.org/). 130 
Samples were used with informed consent conforming to the ethical guidelines of the 1975 131 
Declaration of Helsinki and study protocols were approved by the NRES Committee East 132 
Midlands (reference 11/EM/0323). Viral loads (VLs) were measured by COBAS TaqMan PCR 133 
(Roche) according to the manufacturer’s protocol. Viral loads were expressed as 134 
international units (IU) / ml.  135 
 136 
2) Mixed genotype plasma samples. Two samples from the UK Quality Control for Molecular 137 
Diagnostics (QCMD) HCV genotype panel containing mixed genotypes (HCVG10-02: 138 
genotypes 1b and 3a and HCVG10-04: genotypes 3a and 5a) were used. Artificial mixtures of 139 
plasma samples from HCV Research UK containing different geno(sub)types were created in 140 
defined ratios using viral loads measured by COBAS TaqMan PCR (Suppl. Table S1B).  141 
 142 
C) In vitro RNA transcripts (IVTs). Full length cDNA clones of the HCV strains H77 and JFH-1 143 
were linearised with XbaI, treated with mung bean nuclease (New England Biolabs) to 144 
remove 5′ end overhangs and purified (PureLink PCR purification kit, Invitrogen). 1μg 145 
linearized DNA template was used for RNA transcription using T7 RNA Polymerase 146 
(MEGAscript, Ambion)  for 1 h at 37˚C. RNA was cleaned up using the RNeasy Kit (QIAGEN) 147 
and the integrity of the RNA analysed by non-denaturing agarose gel electrophoresis. RNA 148 
concentrations were determined using spectrophotometry. Transcripts were diluted in TE 149 
buffer and mixed in ratios at known concentrations before distribution to the four labs 150 
(Suppl. Table S1B).  151 
 152 
Combined, these were used to create the NGS evaluation panel. This comprised: (A) Plasma 153 
samples from 27 individuals infected with single genotypes as determined by the referring 154 
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laboratories and a negative control (Suppl. Table S1A). (B) 7 samples containing a mixture of 155 
two samples of known genotypes spanning G1, 2, 3 and 4 (Suppl. Table S1B). (C) 9 samples 156 
containing RNA transcripts from genotype 1a and 2a in ratios corresponding to 5000:1 157 
through to 1:5000 of 1a and 2a IVTs respectively.  158 
 159 
Sequencing methods.  160 
 161 
Summary. The combined evaluation panel of 43 samples was used to evaluate the 162 
performance of seven sequencing methods developed at four expert centres (G: Glasgow, O: 163 
Oxford, P: PHE and U: UCL).  Each sample was assayed blind using NGS platforms and either 164 
unselected (metagenomic) approaches (G-Meta, O-Meta), probe-based HCV sequence 165 
enrichment (G-SSel, G-Nimb, O-Capt and U-Capt) or HCV-specific PCR amplification and 166 
sequencing (P-PCR). Data from each method were processed using analysis pipelines 167 
established in each centre (Table 1). Processing of read data consensus sequence 168 
construction, assessment of genome coverage and accuracy and quantification of 169 
quasispecies diversity used a common set of tools in an additional centre that coordinated 170 
the analysis (Edinburgh). 171 
 172 
O-Meta and O-Capt: Total RNA was extracted from 500µl plasma using the NucliSENS 173 
magnetic extraction system (bioMerieux) and eluted into 30µl of kit buffer. Metagenomic 174 
libraries were prepared using the NEBNext® Ultra™ Directional RNA Library Prep Kit for 175 
Illumina® (New England Biolabs); 5µl (maximum 10ng) RNA was fragmented (5 or 12 minutes 176 
at 94°C), reverse-transcribed, amplified (5-18 PCR cycles) using indexed primers, then 177 
purified into 0.85× volume Ampure XP (Beckman Coulter). Libraries were quantified (Quant-178 
iT™ PicoGreen® dsDNA Assay; Invitrogen) and assessed for purity (TapeStation with D1K 179 
High Sensitivity kit; Agilent) before pooling in equimolar proportions and final normalisation 180 
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(KAPA SYBR® FAST qPCR Kit; Kapa Biosystems). Metagenomic virus RNA-Seq libraries were 181 
sequenced with 100b paired-end reads (PE) on the Illumina HiSeq 2500 with v3 Rapid 182 
chemistry.  183 
 184 
For capture, a 500ng aliquot of pooled O-Meta library was enriched using equimolar-pooled 185 
120nt DNA oligonucleotide probes (10) using the xGen® Lockdown® protocol from 186 
Integrated DNA Technologies (IDT).  Enriched pools were re-amplified (12 cycles on-bead 187 
PCR), re-purified and normalised using qPCR and 100b PE reads were sequenced on a single 188 
run of the Illumina MiSeq (v2 chemistry). 189 
 190 
G-Meta and G-Capt: RNA was extracted from 200µl plasma using the Agencourt RNAdvance 191 
Blood kit (Beckman Coulter) eluted into 11µl of  water, then reverse transcribed using 192 
SuperScript III (Invitrogen) with random hexamers and a NEB Second Strand Synthesis kit 193 
(New England Biolabs) for library preparation using the KAPA Library Prep kit (KAPA 194 
Biosystems) with index tagging by 16 cycles of PCR using KAPA HiFi HotStart (KAPA 195 
Biosystems) and NEBNext Multiplex Oligos for Illumina Index Primers Sets 1 and 2 (New 196 
England Biolabs). Libraries were quantified by Qubit (ThermoFisher), and TapeStation; 197 
(Agilent) and pooled at equimolar concentrations for sequencing on the Illumina MiSeq 198 
platform (v3 chemistry). 199 
 200 
For capture, Pooled G_meta libraries were enriched by either the NimbleGen SeqCap EZ 201 
System (Roche) (G_Nimb) or the SureSelect Target Enrichment System (Agilent) (G_SSel), the 202 
latter with double-scale reactions and hybridization for 36 hours rather than the 203 
recommended 16-24 hours, then sequenced on the Illumina MiSeq platform using v3 204 
chemistry (Illumina). 205 
 206 
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U-Capt: RNA was extracted (QIAamp viral RNA mini kit; Qiagen, 52904) from 140 µl of 207 
plasma eluted into 60 µl of AVE buffer, RNA was concentrated to 10 µl either using a Speedy-208 
vac at 65°C or by RNeasy MinElute Cleanup Kit before first strand cDNA synthesis 209 
(Superscript III Reverse Transcriptase kit; Life Technologies).  210 
 211 
Second strand cDNA synthesis used 20 µl from first stand synthesis (Second Strand cDNA 212 
synthesis kit; NEB). SureSelectXT Target Enrichment (Agilent) was used for library 213 
preparation, hybridisation and enrichment. 120-mer RNA baits spanning 953 GenBank HCV 214 
reference genomes were designed by the PATHSEEK consortium and synthesised by Agilent 215 
Technologies. Purified ds cDNA was quantified (Qubit dsDNA HS assay kit; Life Technologies) 216 
and sheared (200-500 ng ds cDNA for 150 seconds using Covaris E220 focused ultra-217 
sonication system). Samples containing <200 ng were bulked with human gDNA (Promega) 218 
prior to shearing. End-repair, adapter ligation, hybridisation, PCR pre and post-capture and 219 
all post-reaction clean-up steps were performed according to the SureSelectXT Automated 220 
Target Enrichment for Illumina Paired-End Multiplexed Sequencing 200 ng protocol (version 221 
F.2) on the Bravo platform WorkStation B from Agilent Technologies. All recommended 222 
quality control steps were performed on the 2200 TapeStation (Agilent Technologies). The 223 
samples were sequenced on an Illumina MiSeq sequencing platform with 500 bp v2 reagent 224 
sets. Base calling, adapter trimming and sample de-multiplexing were generated as standard 225 
producing paired FASTQ files for each sample. 226 
 227 
P-PCR: Viral RNA was extracted from 200 µl plasma (Qiagen Ultra Sens extraction kit).  HCV 228 
genotype was defined using a pan-genotypic sequencing assay of the NS5B region as 229 
previously described (11).  Whole genome sequencing used HCV genotype specific primers in 230 
five or six overlapping amplicons for each genotype/subtype (Suppl Table S2). Viral RNA was 231 
amplified (single-step RT-PCR; Superscript III Reverse Transcriptase, Invitrogen), followed by 232 
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nested or semi-nested PCR.  PCR products were purified (QIAQuick kit; QIAGEN) and 233 
quantified (Qubit® dsDNA Broad Range and High Sensitivity Assay Kits and the Qubit® 2.0 234 
Fluorometer; Life Technologies). Alternate amplicons were pooled in two reactions of 235 
equimolar amounts and 1 ng/µl of the pooled DNA was used for library preparation (Nextera 236 
XT DNA sample preparation kit; Illumina) according to manufacturer's instructions.  Indexed 237 
libraries were sequenced using Illumina MiSeq deep sequencing reagent kit v2 (Illumina). 238 
 239 
For quality assurance of primers used for amplification, these were frequently validated by 240 
checking alignments of all publicly available genome sequences to detect any intra-genotype 241 
variations; new batch of primers are validated side-by-side with old primer stock on samples 242 
that were previously amplified and sequenced.  Primers stocks are also revalidated every 6 243 
months. 244 
 245 
Several measures were in place to prevent and monitor PCR contamination, including:  246 
 247 
(i) Inclusion of negative controls within each batch of extractions and amplifications 248 
(ii) Standard PCR workflows such as directional material flow, geographical and 249 
temporal separation of PCR stages, reagent aliquoting etc 250 
(iii) Bioinformatics pipeline that includes the use of a depth thresholds >100 (as 251 
contaminants rarely have a depth greater than 10) 252 
(iv) Phylogenetic tree-based contamination checking that includes all sequences within a 253 
run and those processed on several previously immediate runs 254 
 255 
Bioinformatics processing  256 
Oxford: As described previously (10, 12), low-quality bases were trimmed from de-257 
multiplexed sequences using QUASR v7.01 258 
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(www.bioconductor.org/packages/release/bioc/html/QuasR.html) and adapter sequences 259 
removed using CutAdapt v1.7.1 (http://cutadapt.readthedocs.io/en/stable/index.html). 260 
Human sequences were excluded by mapping to the HG19 human reference genomes with 261 
Bowtie v2.2.4 (http://bowtie-bio.sourceforge.net/index.shtml) and HCV- derived reads were 262 
aligned to a local BLAST database of 165 HCV genomes collated by the ICTV (International 263 
Committee on the Taxonomy of Viruses). PE reads were assembled de novo into contiguous 264 
whole genome sequences with Vicuna v1.3 and finished with V-FAT v1.0 265 
(http://www.broadinstitute.org/scientific-community/science/projects/viral-genomics/v-266 
fat). Reads were mapped back to the assembly using Mosaik v2.2.28 267 
(http://gkno.me/pipelines.html#mosaik) and variants were called by V-Phaser v2.0 268 
(http://www.broadinstitute.org/scientific-community/science/projects/viral-genomics/v-269 
phaser-2). 270 
 271 
Glasgow: Fastq file quality was assessed using FastQC 272 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Sam files were created by 273 
mapping against 64 whole genome HCV reference sequences using Tanoti and de novo 274 
assembly using the MetAmos pipeline (http://www.cbcb.umd.edu/software/metamos/). 275 
Assemblies were viewed using UGene (http://ugene.net/). Genotype ratios were calculated 276 
using a kmer-based approach using kmers unique to each genotype.  277 
 278 
UCL: Genome mapping, assembly and finishing was performed using CLC Genomics 279 
Workbench (Qiagen version 7.5/7.5.1). All read-pairs were subject to quality control and 280 
reads were quality trimmed based on a cut-off average Phred score of 30 and the presence 281 
of ambiguous nucleotides. Adapter trimming of Illumina-specific adapters was performed on 282 
all samples. Trimmed reads were mapped against a GenBank reference list containing 953 283 
HCV genomes to identify the best matching HCV reference. Each sample was mapped using 284 
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the default affine gap cost parameters followed by local realignment. Total base counts at 285 
each genomic position were recorded using an in-house script.   286 
 287 
PHE: A subset of the MiSeq PE reads from each FATSQ file was compared to a local database 288 
of 1,684 HCV whole genome reference sequences using BLAST to identify an optimum 289 
reference sequence for mapping and BWA-MEM [v0.7.5] 290 
(https://www.msi.umn.edu/sw/bwa). Utilising SAMtools 291 
(http://samtools.sourceforge.net/mpileup.shtml) the resulting files were converted into 292 
BAM format. In-house software (QuasiBAM) generated consensus sequences for minority 293 
variants. Procedures were automated using a computational pipeline developed in-house 294 
with Python and C++. For detection of multiple HCV genotypes, FASTQ files derived from 295 
amplification of the NS5B genotyping fragment were digitally normalised (Kmer software; ) 296 
to reduce the number of duplicate reads and assembled (SPAdes v3.5.0; 297 
http://bioinf.spbau.ru/spades). Contigs were compared with a database of NS5B fragments 298 
representing different HCV genotypes using BLAST and stitched together to give the longest 299 
possible sequence from each genotype detected by the contig BLAST process. Where 300 
multiple genotypes were detected the contigs were trimmed to match the length of the 301 
shortest sequence. The total population of reads (non-normalised FASTQ files) were then 302 
reference mapped against the genotype-specific assembly contigs using BWA and the 303 
proportion of reads mapping to each genotype calculated using the statistics programs in 304 
the BamTools suite. 305 
 306 
Consensus sequence generation. For all methods, a majority base consensus sequence was 307 
calculated at each nucleotide site possessing 10 or more base reads. A global consensus 308 
sequence was generated similarly as a majority consensus sequence for the 7 different 309 
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sequencing methods. Any assembled sequence that was >5% divergent from generated by 310 
other NGS methods were discarded.  311 
 312 
PCR amplicon sequencing. A genotype 1-specific PCR was used to amplify sequences in the 313 
NS3 and NS5B regions (positions 3288-5727 and 7407-9366 respectively; total 4100 bases) 314 
from genotype 1a and 1b panel members (n-12). Sanger sequencing used the dideoxy ABI 315 
sequencing systems in both directions using overlapping internal primers (Supplementary 316 
Table S2).  Sequences were analyzed using Sequencher software (Gene Codes) and aligned 317 
using subtype-specific consensus sequences. 318 
 319 
Sequences obtained from each method were compared with those derived from NGS 320 
methods (global consensus) and numbers of nucleotide and amino acid sequence 321 
differences recorded using the program Sequence Dist in the SSE package.  322 
 323 
RAV analysis 324 
For the RAV analysis, positions of interest were identified in the GenBank reference Hepatitis 325 
C strain H77 polyprotein gene, complete coding sequence (AF011751). Each reference used 326 
for mapping was aligned to the HCV strain H77 reference to standardise the positions of 327 
interest and the counts for each base were identified at the DAA associated positions.  328 
 329 
Accession numbers. HCV-specific reads for the 43 samples have been submitted to the 330 
European Nucleotide Archive (ENA) under projects PRJEB11791 (Oxford), Consensus 331 
nucleotide sequences of HCV and human pegiviruses have been submitted to GenBank and 332 
have been assigned the accession numbers from KU180708 to KU180731. 333 
 334 
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Statistics. Spearman’s Rank-Order correlation test was used to test the significance of the 335 
association between viral load and HCV read counts. The Kruskal-Wallis non-parametric one-336 
way test of variance was used to compare detection and assembly of genotype-1/non-337 
genotype-1 HCV reads. P<0.05 was considered significant.  338 
 339 
 340 
Results  341 
 342 
HCV read depths and genome coverage. The abilities of different NGS methods to recover 343 
HCV sequences from samples with varying viral loads was compared (Figure 1). Each method 344 
was effective at detecting HCV sequences in most or all panel samples with a wide range of 345 
viral loads, including those as low as 2000 IU/ml. There was a significant association between 346 
read counts and viral loads using both metagenomic and enrichment methods (Figure 1), but 347 
not after PCR pre-amplification where similar read numbers were obtained over a large viral 348 
load range (Figure 1C). Collectively, enrichment consistently recovered more HCV sequence 349 
reads than metagenomic methods (Figure 1D). There was no evidence for genotype 1 or 350 
non-genotype 1 RNA sequences being preferentially detected by any method (p > 0.05). 351 
 352 
Reads were assembled by mapping to the closest available reference sequences or de novo 353 
(Table 1) and a multiple alignment of the assemblies inferred. Majority rule consensus 354 
sequences were inferred from the reads mapped to the assembly and analysed for 355 
completeness. Complete genome sequences (>95% of H77 sequence length) were 356 
assembled for the majority of samples by each method (Figure 2). However, particularly 357 
using metagenomic methods, only partial assemblies were generated from samples with 358 
lower viral loads. There was no evidence that non-genotype 1 samples were less effectively 359 
assembled than genotype 1 for all methods (p > 0.05).  360 
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 361 
Inspection of read depth across each consensus sequences showed each method yielded 362 
relatively uniform coverage across the genome (Figure 3A-C). In general, read depth across 363 
the genome was more uniform for the metagenomic methods (Figure 3A, Suppl Fig S1A, Z-364 
scores ranging from -2 to +2).  The lowest coverage for all methods were the 5’ untranslated 365 
regions (UTR) and the region beyond the 3’ poly-U tract (Suppl Figure S2). No sequences 366 
were complete at the 5’ and 3’ ends as defined by the sequence span of the H77 sequence. 367 
PCR pre-amplification necessarily limited the coverage of the P-PCR method to positions of 368 
the nested sense primer in 5’ UTRs and 3’UTRs. Similarly, the reference sequences used for 369 
assembly of sequence reads in the G-Meta, G-SSel and G-Nimb lacked the X-tail sequence 370 
beyond the poly-pyrimidine tract and could not be assembled beyond this point. Only the 371 
sequences generated by O-Meta and O-Capt were assembled in the highly structured X-tail. 372 
 373 
Accuracy of assembled HCV sequences. The genotype of HCV in sequences assembled from 374 
each sample was determined by sequence comparisons with reference HCV strains (Figure 4 375 
and Suppl. Table S1). Genotype assignments were concordant between NGS methods and 376 
with the clinical genotyping assays . HCV sequences assembled by NGS were analysed both 377 
by comparison of majority (consensus) sequences and through within-site variability. 378 
Majority sequences generated by different NGS methods were generally identical or similar 379 
to each other (Figure 4). However, several assembled sequences failed to match the 380 
consensus sequence of other NGS generated sequences (shaded in green) even if NGS 381 
defined the same subtype. For one sample (sP799685), four different HCV strains (>5% 382 
divergent from each other) were detected by different methods (shaded red). Samples 383 
yielding discrepant sequences were typically those with low coverage and lower viral loads 384 
(column 2, Figure 4), particularly the incomplete sequences generated by G-Meta and G-SSel 385 
methods. The PCR methodology for HCV genotype 2 in particular frequently failed to 386 
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generate whole genomes. The following sequences were excluded from further analyses of 387 
viral heterogeneity since the incompleteness of sequence representation precluded 388 
generating an informative sample consensus sequence: sP546783, sP371169, sP800022, 389 
sP510486 and sP799685. 390 
   391 
To analyse the similarity of sequences generated by each NGS method, they were compared 392 
to a global consensus, representing the combined consensus of the different sequencing 393 
methods. Few consensus sequences were identical to global consensus over the whole 394 
genome, with many having 10 or more differences (Figure 5A, 5B). These differences were 395 
concentrated in the hyper-variable regions (HVR1 (E2): 384-410, HVR2 (E2): 473-480, V3 396 
(NS5A): 2356-2379, H77 coordinates (12)) and surrounding E1 and E2 regions (Figures 3D-397 
3F), and divergence was particularly evident for genotype 2 samples (Suppl Figure S3). 398 
Different NGS methods showed similar diversity of sequences with the exception of P-PCR 399 
which showed a median of 12 and 9 nucleotide and amino-acid differences respectively from 400 
the global consensus over the complete genome (Figure 5A, 5B).  401 
 402 
For comparative evaluation of sequencing accuracy with standard PCR/sequencing 403 
methodologies, sequences were amplified using separate NS3 and NS5B PCRs (positions 404 
3288-5727 and 7407-9366 respectively; total 4100 bases) of genotype 1 panel members 405 
(identified in Table S1). Sequences directly obtained by Sanger sequencing from the 406 
amplicon were compared with the global consensus sequence derived from NGS (Figure 5D). 407 
Most samples showed sequence identity between the two methods. Sequence differences 408 
between methods occurred predominantly at polymorphic sites where the base called in the 409 
PCR-derived sequence was represented at varying proportions among NGS sequences but 410 
not called in the majority NGSS consensus sequence (data not shown).  411 
 412 
 o
n
 July 26, 2016 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jcm.asm.org/
D
ow
nloaded from
 
Thomson, Ip et al., (Manuscript) 
Page 17 / 33 
To further determine the accuracy of sequences generated by NGS methods, RNA transcripts 413 
of HCV genotypes 1a and 2a were sequenced by representative metagenomic and 414 
enrichment methods (Ox_Meta and Ox_Capt) to estimate a technical error rate. Sequence 415 
errors have originated from misincorporation errors during reverse transcription of the RNA 416 
sequences, errors during strand extension during sequencing and finally bioinformatic errors 417 
during base calling and sequence assembly. However, majority consensus sequences of both 418 
transcripts were identical to those of both original clones using the two methods (Table 2), 419 
indicating that methods-associated technical errors were not the cause of sequence 420 
differences in consensus sequences of the panel samples between methods.    421 
 422 
Further evidence that the differences between consensus sequences generated by different 423 
methods reflected biological diversity, relative frequencies of synonymous and non-424 
synonymous substitutions were calculated for the non-structural gene region (Figure 5C); 425 
natural variability typically occurs at synonymous sites (dN/dS ≤ 0.2 in the HCV genome) 426 
while those arising from technical error associated with the NGS method would be unbiased 427 
(dN / dS ≈ 1). All sequences showed dN/dS ratios below 1, most substantially lower (< 0.2) 428 
and consistent with naturally occurring variability. To investigate whether the particularly 429 
divergent sequences (≥ 5 nucleotide differences from the sample consensus) were 430 
specifically those originating from read / assembly errors, they were plotted with a different 431 
symbol (grey filled circles, Figure 5C). There was little association between degree of 432 
sequence divergence and dN/dS ratio.  433 
 434 
Assessment of quasispecies diversity of HCV. The observed diversity of sequences may 435 
originate from naturally occurring variability of variants within samples (“quasispecies”) or 436 
technical sequencing errors. The contribution of the latter technical errors to quasispecies 437 
diversity was determined though analysis of base counts at each site of sequences derived 438 
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from the RNA transcripts of genotypes 1a and 2a (Table 2). Analysis of individual base reads 439 
at each site revealed that only a small minority of the ≈9500 sites were polymorphic at the 440 
5% level, ranging from 18 to 42.  441 
 442 
This diversity was formally quantified through calculation of Shannon entropy where at each 443 
nucleotide site, 0 represents no variability, 1 represents equal frequencies of 2 bases, and 2 444 
represents equal frequencies of all four bases. Mean values for the transcripts (0.0065-445 
0.0158) were substantially lower than observed for RNA sequences present in the panel 446 
samples (Table 2; Figs. 5D-5F). Variability was evident between sequencing methods, with 447 
less diversity observed for pre-PCR or metagenomic sequencing methods  Diversity 448 
increased significantly with increasing viral load using metagenomics, but to a much lesser 449 
extent with enrichment (Figure 5D, 5F).  450 
 451 
As with the analysis of sequence differences from the consensus (previous section), within-452 
population variability should be greater at 3rd codon positions (where changes are more 453 
likely to be synonymous) if the detected within-site diversity is naturally generated. This was 454 
indeed the case, with 2-3 times greater Shannon entropy values at 3rd codon positions 455 
compared to 1st and 2nd both over the whole coding region (Figure 5D) and in particular if 456 
analysis was restricted to the non-structural gene region (Figure 5E). As anticipated, no bias 457 
towards greater entropy values at 3rd codon positions was evidence in the transcript 458 
sequence (Table 2).   459 
  460 
Detection of mixed genotypes. The ability of different NGS methods to detect co-infections 461 
with more than one genotype was determined using a panel of plasma samples containing 462 
RNA representing different genotypes in different ratios. These included the two mixed 463 
infection plasma samples distributed as part of a UK National quality control panel (QCMD1, 464 
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2), five plasma samples generated from mixture of component plasmas with measured viral 465 
loads and calculated ratios (sP731482, sP104509 and JW1-3), a series of RNA transcripts of 466 
genotypes 1a and 2a in a wider range of ratios (IVT1-5, Suppl Table S1B). 467 
 468 
The reads from each sequencing method were processed using an appropriate 469 
bioinformatics pipeline developed by the expert centre to infer the genotype and consensus 470 
sequence for up to two populations of reads in each sample (Supplementary File 2). Ratios of 471 
reads were compared to those of input RNA copies (Figure 7). For all methods, there was a 472 
close and reproducible relationship between input proportions of plasma and transcript 473 
sequences of different genotypes, and the relative frequencies of reads by NGS. The majority 474 
of observed ratios fell close to the x=y line added to each graph.  475 
 476 
DAA resistance mutation detection. Frequencies of naturally occurring RAVs in NS3, NS5A 477 
and NS5B genes were compared between the sequencing methods for samples in the 478 
evaluation panel; all subjects were DAA treatment-naïve at the time of sample collection 479 
(Figure 8A, 8B). Potential RAVs were most frequently detected in the NS3 and NS5A genes, 480 
particularly in non-genotype 1 sequences, with highly infrequent detection of resistance at 481 
sites associated with inhibitors of the NS5B polymerase (eg. S282 and L419). Several RAVs 482 
were found as majority variants (such as the NS3 Q80K mutation in genotype 1a strains; 483 
Figure 8A) and these were consistently detected by different sequencing methods. However, 484 
methods varied considerably in their detection of minor populations of RAVs (shaded 485 
yellow), with several inconsistencies in their detection or percentage population 486 
representations. In general, Glasgow metagenomic and both Glasgow and Oxford capture 487 
methods recorded highest frequencies of minor populations of RAVs in all three genes but in 488 
many cases, different polymorphic sites were identified in different samples.  489 
 490 
 o
n
 July 26, 2016 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jcm.asm.org/
D
ow
nloaded from
 
Thomson, Ip et al., (Manuscript) 
Page 20 / 33 
Co-infecting viruses. Metagenomic sequence libraries generated by G-Meta and O-Meta 491 
were screened by blastn for other human viruses using example sequences obtained from 492 
Refseq (NCBI). Of the 6,783 human viruses screened (NCBI RefSeq viruses r63: 493 
ftp://ftp.ncbi.nlm.nih.gov/refseq/release/viral/), three samples contained some human 494 
pegivirus (HPgV) sequences. One sample, from patient sP104509, could be assembled into a 495 
single contig with 100% coverage of the reference, high read depth (1,600 for O-Meta), and 496 
virtually identical assemblies were derived via the O-Meta and G-Meta methods. 497 
 498 
Discussion 499 
Whole-genome sequencing of HCV from clinical samples has until now been considered a 500 
costly, laborious and technically challenging procedure that has not been adopted in routine 501 
clinical practice. The major challenge to conventional PCR Sanger sequencing is the inherent 502 
diversity of the virus that limits the degree of primer match with different strains and 503 
genotypes, generating consensus sequences of limited value and often failing to generate 504 
amplicons for large parts of the genome. In contrast, NGS technologies have the potential to 505 
generate full-length HCV genomic sequences that enable (i) accurate inference of the full-506 
length, majority consensus HCV genome in the sample and the detection of (ii) minor 507 
circulating viral populations within individuals, (iii) mixed geno(sub)type infections and (iv) 508 
the presence of treatment associated RAVs along the entire genome. All four metrics will 509 
inform future treatment decisions in the new era of DAA therapies.  510 
 511 
In order to compare and measure the consistency of different approaches, we evaluated 512 
three NGS methodologies including metagenomic sequencing, target enrichment using both 513 
DNA and RNA oligonucleotide probes, and the generation of multiple amplicons by PCR 514 
before NGS. For this we used clinical samples containing a single genotype, or a mixture of 515 
different genotypes or subtypes, across a range of HCV viral loads. All NGS methodologies 516 
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were able to generate whole genomes from clinical samples and more accurately defined 517 
HCV subtype than the probe based assay that is commonly used in clinical practice.  518 
However, we identified clear advantages and disadvantages to each. The metagenomic 519 
approach is fundamentally attractive since this technique has the capacity to detect other 520 
pathogens that may be clinical relevant, and stored metagenomic data can be utilised for 521 
viral discovery; as proof of principle we were able to recover complete HPgV genome 522 
sequences in clinical HCV samples using this approach. However, metagenomics provided 523 
significantly lower depth of coverage than other methodologies, and performed less well at 524 
lower HCV viral loads in generating WGS. Furthermore, this approach was relative costly for 525 
the numbers of HCV reads generated since the vast majority of reads obtained are of human 526 
origin and were discarded.  527 
 528 
NGS that relies on PCR amplification is currently utilised for the detection of viral resistance. 529 
However, in our experience the development of full-length sequence using this approach in 530 
even a small number of patients was relatively laborious requiring multiple PCR reactions 531 
per sample, compared to a single library per sample for metagenomics and the subsequent 532 
pooling of 96 libraries in a single tube for sequence capture. It was therefore less suited in its 533 
current stage of development for high-throughput analysis. Furthermore prior knowledge of 534 
viral genotype was required; the failure to generate HCV amplicons was particularly evident 535 
for HCV genotype 2 since there are currently relatively few complete genome sequences for 536 
this genotype available to inform primer design. A linear relationship between HCV viral load 537 
and the number of HCV reads was observed with both metagenomic and target enrichment 538 
sequencing but not PCR pre-amplification where similar numbers of HCV reads were 539 
obtained irrespective of viral load. Amplification of viral sequences prior to NGS is therefore 540 
likely to be of particular value for low HCV viral load samples. 541 
 542 
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Variability in coverage and sequencing depth across the genome was observed with all 543 
methods. This may originate through variability in the degree of match between probe or 544 
primer sets to the target viral sequence and therefore differences in the efficiency of target 545 
capture or amplification. We have recently shown that introducing probes to better 546 
represent known sequence variation can reduce bias in coverage due to probe-target 547 
divergence to zero (10).  However, incomplete coverage was not a consistent problem for 548 
any of the capture methods, which in fact provided substantially greater depth of HCV 549 
coverage than metagenomic methods that were probe-independent. Capture methods, 550 
overall, were better able to generate WGS for the same sequencing effort across a wide 551 
range of HCV viral loads. 552 
 553 
Overall, there was concordance in the HCV genotypes identified by all NGS methods at each 554 
centre. While the majority of consensus sequences obtained by each sequencing centre 555 
were identical to each other, in a minority of cases unrelated sequences were obtained; this 556 
could be explained by sequencing error, cross-contamination or by preferential sequencing 557 
of one strain over another in samples from patients with mixed strain infection. Sequencing 558 
error was considered unlikely to have contributed significantly to these differences as the 559 
dN/dS ratio was consistently low with an increase in variability at the 3rd codon site (usually a 560 
synonymous position) in keeping with natural occurring variability. Furthermore, NGS of RNA 561 
transcripts demonstrated extremely low frequencies of sequencing errors from a defined 562 
template, while NGS-derived sequences differed little from Sanger-sequenced amplicons 563 
from the NS3 and NS5A/5B regions (Figure 5D).  564 
 565 
Infection with mixed HCV genotypes has been frequently reported (14-16), but its true 566 
incidence is unknown since existing genotyping assays are not designed to assess this. The 567 
impact on clinical care of mixed-genotype infections is not yet clear but theoretically, more 568 
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drug resistant genotypes such as genotype 3 could result in treatment failure as a result of 569 
emerging dominance during treatment (17). NGS methodologies that routinely captured this 570 
data would therefore represent an important advance. For all methodologies, we 571 
demonstrated that NGS was remarkably accurate in determining the ratio of mixed 572 
genotypes in clinical samples. In addition to genotyping, we assessed the presence or 573 
absence of resistance mutations within NS3, NS5A and NS5B using each sequencing method. 574 
Majority variants were reliably detected with all methods but variation was noted in 575 
minority variant detection. Both this data and the mixed genotype experiments suggest that 576 
the detection of minority variants is less reliable at lower ratios. 577 
 578 
In summary, we provide a comprehensive analysis of three NGS sequencing methodologies 579 
for the generation of full length HCV viral genomes. Our data suggests that HCV target 580 
enrichment is highly effective, suitable for high-throughput and is relatively effective at low 581 
viral loads generating deep coverage along the HCV genome. The metagenomic approach 582 
remains attractive because the libraries generated may be probed for additional pathogens 583 
that may contribute to disease development and which will provide a rich dataset for future 584 
research endeavours in pathogen discovery. PCR pre-amplification is relatively laborious but 585 
may still have a role in very low viral load samples. We have show that WGS of HCV is readily 586 
achievable across multiple sites in the UK. In the era of DAA therapy, where a single course 587 
of therapy routinely costs >£30,000, we believe that NGS for the generation of WGS that 588 
accurately defines viral genotype, and readily detects both RAVS and mixed infections should 589 
be routinely employed. Sequencing by any of the methods evaluated in the current study 590 
can be achieved at a cost of approximately £120/sample, comparable to that of the existing 591 
clinical genotyping assays. The generation of WGS for HCV nationwide would be hugely 592 
informative, guiding clinical practice whilst concurrently providing an invaluable dataset for 593 
epidemiology studies and future research.  594 
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Table 1: Sequencing methods and analysis pipelines evaluated at each sequencing centre 679 
 680 
Centre Method Code Sequencing method Analysis strategy 
Oxford Metagenomic O-Meta Illumina RNA-Seq of 
total plasma RNA. 
Bespoke bioinformatics 
pipeline to infer 
metagenomic, consensus 
and sub-population level 
information1. 
IDT O-Capt Genotype-specific HCV 
capture using IDT 
probes followed by 
Illumina RNA-Seq1.  
Glasgow Metagenomic G-Meta Illumina RNA-Seq of 
total plasma RNA  
FastQC, Tanoti, in house 
resistance mutation tools, 
de novo assembly using 
MetAmos   
SureSelect G-Ssel Genotype-specific HCV 
capture using 
SureSelect DNA probes 
followed by Illumina 
RNA-Seq 
FastQC, Tanoti, in house 
resistance mutation tools, 
de novo assembly using 
MetAmos   
NimbleGen G-Nimb Genotype-specific HCV 
capture using 
NimbleGen RNA probes 
followed by Illumina 
RNA-Seq 
FastQC, Tanoti (REF under 
review), in house 
resistance mutation tools, 
de novo assembly using 
MetAmos   
UCL SureSelect U-Capt SureSelectXT Target 
Enrichment library 
preparation and 
hybridisation and 
enrichment using 
custom designed RNA 
probes followed by 
Illumina DNA-Seq  
Genome mapping (best 
ref.), assembly and 
finishing using CLC 
Genomics Workbench 
from Qiagen. DAA 
analysis using in-house 
script. 
PHE Pre-PCR P-PCR Genotype-specific 
nested PCR of 5-6 
overlapping fragments 
followed by Illumina 
sequencing. 
Contig assembly by 
SPAdes 3.5.0. HCV contigs 
longer than 250nt 
assembled and PCR 
fragments combined 
using Sequencher 5.0. 
Reads were re-mapped to 
assembled sequences 
using BWA 0.7.5.  
 681 
1 Bonsall D, Ansari MA, Ip C et al. ve-SEQ: Robust, unbiased enrichment for streamlined 682 
detection and whole-genome sequencing of HCV and other highly diverse pathogens 683 
(version 1; referees: 1 approved) F1000Research 2015, 4:1062 (doi: 684 
10.12688/f1000research.7111.1)  685 
 686 
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 688 
Table 2. Error rates of representative sequencing methods for HCV genotype 1a and 2a 689 
transcripts 690 
 691 
Method Transcript Accuracya Unresolved 
sites (>5%)b 
Shannon entropy at codon position
 All sites 1 2 3
Ox_Meta 1a_AF011751 100% 35 0.0158 0.0150 0.0157 0.0135
 2a_AB047639 100% 42 0.0129 0.0132 0.0143 0.0166
Ox_Capt 1a_AF011751 100% 25 0.0079 0.0077 0.0075 0.0075
 2a_AB047639 100% 18 0.0065 0.0065 0.0029 0.0032
 692 
aSequence concordance of majority consensus sequence with the sequence of the clone 693 
bNumber of ambiguous sites (discordant reads forming >5% of total)  694 
 695 
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 697 
Figure Legends 698 
 699 
Fig 1: Relationship between viral loads and read counts for each method 700 
Total HCV-specific bases read from each sample (y-axis, log scale) was compared with viral 701 
loads separately for (A) target enrichment (B) metagenomic library and (C) sequence pre-702 
amplified by PCR, on a common x/y scale. Genotype 1 and non-genotype 1 samples are 703 
indicated according to the key. The significance of the association between viral load and 704 
read counts was calculated by Spearman’s rank-order correlation test; values of rs and p 705 
values are provided in inset boxes. (D) Distribution of viral loads by method with logarithmic 706 
mean values shown below the x-axis; the box and whisker plot shows median, 67 and 95 707 
percentiles.  708 
 709 
Fig 2: Relationship between viral load and completeness of the HCV consensus sequence 710 
from each method 711 
Proportion of whole genome sequenced was compared with viral loads separately for (A) 712 
Target enrichment (B) metagenomics and (C) sequence pre-amplified by PCR (plotted on a 713 
common x/y scale). Sequence completeness was expressed as a percentage, assuming a 714 
genome length of 9,650 bases. Genotype 1 and non-genotype samples are indicated 715 
according to the key. The significance of the association between viral load and genome 716 
coverage was calculated by Spearman’s rank-order correlation test; values of rs and p values 717 
are provided in inset boxes.  718 
 719 
Fig 3: Variability in read depth across the HCV genome coverage, and divergence from a 720 
global consensus for each of the sequencing methods 721 
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(A, B and C) Mean read coverage across the HCV genome by different NGS methods. Mean 722 
coverage was calculated as the number of bases at each site as a proportion of total reads 723 
for the sequence (expected mean value 0.00014); mean values were calculated from 724 
samples with >100,000 total reads. Genome positions were based on the H77 reference 725 
sequence. A genome diagram of HCV drawn to the same scale as the x-axis is included 726 
below. A plot of Z-scores is provided in Supplementary Data (Figure S1).  (D, E and F). 727 
Divergence between the global consensus and individual consensus sequence generated by 728 
different methods were calculated for a sliding window of 250 bases centred on every 30th 729 
base. Mean divergence values for each sequencing method at each site (expressed as 730 
proportional distance (p-distance) were plotted for positions homologous to the H77 731 
reference strain. Genomic features of the HCV genome are shown below, with structural 732 
genes shown in red. A comparable plot of mean values for each genotype is shown in Figure 733 
S3.  734 
 735 
Fig 4: Comparison of the completeness of consensus sequences and their genetic 736 
relatedness to each other 737 
Percentage sequence completeness for coding regions is given for each sample. Consensus 738 
sequences were assembled from the panel samples by each NGS method and used to define 739 
HCV genotype and compared with the genotype identified by conventional genotyping assay 740 
(column 3). Samples have been ranked by viral load (column 2; highest to lowest). 741 
Assembled sequences that correspond to the global consensus are shown on a grey/white 742 
scale; those that differed by >5% in nucleotide sequence from each other were considered 743 
as separate strains and are shown on a green scale. Sample sP799685 generated a diverse 744 
range of sequences in different NGS methods and it was not possible to generate a global 745 
consensus sequence by combining sequences (red shading).  746 
 747 
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Figure 5:  Assessment of viral diversity; sequence differences between the global 748 
consensus and majority sequences generated by each NGS method, and the association of 749 
HCV viral load with diversity. 750 
 (A, B) Distribution of the numbers of nucleotide and amino acid differences respectively (Y-751 
axis scale, log) between the global consensus sequence and the individual majority-rule 752 
sequences generated by each NGS method (x-axis).  Sequences phylogenetically unrelated to 753 
the global consensus (shaded green in Figure 4) or where there was no global consensus 754 
(shaded red in Figure 5) have been excluded from this analysis. Grey bars represent median 755 
values for the distribution (C) Non-synonymous / synonymous ratio of substitutions between 756 
each assembled sequence and the corresponding global consensus sequence. More 757 
divergent sequences showing ≥ 5 differences from the global consensus are plotted with 758 
grey filled circles. (D) Distribution of nucleotide and amino acid differences between directly 759 
sequenced amplicons derived from the NS3 (positions 3288-5727) and NS5B region 760 
(positions 7407-9366) of 12 samples from the evaluation panel with corresponding regions 761 
from the global consensus obtained by NGS methods.  762 
 763 
Figure 6. Mean Shannon entropy values of NGS generated sequences and relationship with 764 
viral load. Entropy values for polymorphic sites inferred for NGS sequencing methods based 765 
on (A) metagenomic libraries, (B) target enrichment; and (C) PCR-pre-amplification and viral 766 
load are plotted on log scales. (D, E) Entropy values at each codon position in the consensus 767 
sequences inferred by each sequencing method based on (D) the whole genome and (E) the 768 
non-structural regions. 769 
 770 
Figure 7: Capacity of NGS to detect mixed genotype/subtype samples 771 
Observed ratios of NGS read counts between component genotypes gt A and gt B (y-axis) 772 
compared to their input ratios (x-axis), plotted on a log / log scale.  The dotted line 773 
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represents the expected position of data points if the assays were able to detect both input 774 
genotypes (A, B) with equal efficiency.   Samples of mixed genotype of known ratio (the 775 
input ratio) were acquired from QCMD, or through patient samples or in vitro transcripts of 776 
known genotype that were mixed in vitro (listed in Table S1B).  777 
 778 
Figure 8: Frequencies of RAVs in the in the study samples (untreated subjects) 779 
Frequencies of resistance associated mutations NS3, NS5A and NS5B detected by different 780 
sequencing methods, shaded to indicate frequencies. Resistance mutations were present 781 
either as minor variants (around 1-10% of the population; shaded yellow) or represented the 782 
predominant variant in the population (shaded red). Frequency information from samples 783 
with <10 reads at a site were excluded, as were polymorphisms found within a single 784 
sequence. Samples have been grouped by genotype.  785 
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Completeness of sequences not matching global consensus
Completeness of sequences where no global consensus was available
Sequencing Method
Sample Data Whole RNA Target-enriched PCR
Sample VL-IU/ml G-Meta O-Meta G-SSel O-Capt G-Nimb U-Capt P-PCR
sP528652 19256
0% 99% 99% 100% 100% 100% 100%
sP915548 242190 100% 98% 100% 100% 100% 99% 100%
sP883026 1640152 100% 100% 100% 100% 100% 100% 100%
sP824545 195214 100% 100% 100% 100% 100% 100% 100%
sP731482 1447136 98% 98% 98% 99% 99% 100% 100%
sP495677 1782930 100% 100% 100% 100% 100% 99% 100%
sP312482 335842 100% 100% 100% 100% 100% 99% 99%
sP841485 1795374 100% 100% 100% 100% 100% 100% 99%
sP237998 425444 100% 100% 100% 100% 100% 100% 100%
sP256432 877020 100% 100% 100% 100% 100% 99% 100%
sP104509 18214
sP546783 2230 27% 18% 27% 40% 49% 98% 99%
sP643870 402416 100% 100% 100% 100% 88% 100% 100%
sP575531 17838 99% 95% 96% 99% 99% 100% 86%
sP371169 3048 89% 26% 89% 49% 60% 98% 42%
sP800022 10662 99% 85% 100% 98% 100% 0% 99%
sP681788 4559808 100% 100% 100% 100% 100% 100% 81%
sP510486 38072 48% 94% 100% 100% 100% 99% 99%
sP799685 12168 70% 65% 70% 99% 100% 98% 83%
sP260631 29230 100% 100% 100% 100% 99% 100% 99%
sP791266 987104 100% 100% 100% 100% 100% 100% 100%
sP641886 628072 100% 100% 100% 100% 100% 100% 100%
sP759580 468958 100% 100% 100% 100% 100% 100% 100%
sP598047 22754 100% 100% 100% 100% 100% 98% 100%
sP093793 1276834 100% 100% 100% 100% 100% 99% 76%
sP181675 4854384 99% 100% 99% 100% 100% 99% 56%
sP455229 156258 93% 100% 92% 100% 99% 100% 51%
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Codon 122, S Rð
Codon 36, V L/Að
sP528652 1a 0% 0% 0% 0% X 0% 0%
sP915548 1a 0% 0% 0% 0% 0% 0% 0%
sP883026 1a V->A 0.40% 0% 0% 0.01% 0% 1.0% 0.08%
sP824545 1a V->A 1.0% 0% 0% 0.01% 0% 0.21% 0%
sP731482 1a 0% 0% 0% 0% 0% 0% 0%
sP495677 1a X X 0% 0% 0% 0% 0%
sP312482 1a 0% 0% 0% 0% 0% 0% X
sP841485 1a X X 0% 0% 0% 0% X
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1b V->L 0% X 0% 0% X 0.40% 3.5%
sP546783 1b 0% 0% 0% 0% 0% 0% 0%
sP643870 1b 0% 0% 0% 0% 0% 0% 0%
sP575531 1b 0% 0% 0% 0% 0% 0% 0%
sP371169 1b 0% X X 0% 0% 0% 0%
sP455229 1b V->G 4.2% 0% X 0% 0% 0.06% 0.18%
sP800022 2a X X X 0% 0% X X
sP681788 2b 0% 0% 0% 0% 0% 0% 0%
sP510486 2b 0% 0% 0% 0% X 0% 0%
sP799685 2b 0% 0% 0% 0% 0% 0% 0%
sP260631 3a 0% X 0% 0% 0% X X
sP791266 3a 0% 0% 0% 0% 0% 0% X
sP641886 3a X X 0% 0% 0% 0% X
sP759580 3a 0% X 0% 0% 0% 0% X
sP598047 3a 0% 0% 0% 0% X 0% 0%
sP093793 4a 0% 0% 0% 0% 0% 0% 0%
sP181675 4d 0% 0% 0% 0% 0% 0% 0%
Q->K 0% 0% 0% 0.05% X 1.7% 0.55%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Q->K 99% 98% 100% 100% 100% 98% 99%
Q->K 1.7% 0% 0% 0.04% 0% 0.86% 0.21%
Q->K X X 0% 0.09% 0% 3.8% 0.26%
Q->K 2.1% 1.4% 0% 0.01% 0.37% 1.6% X
Q->K X X 0% 0% X 35% X
Q->K 98% 99% 100% 100% X 99% 99%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Q->K 3.6% 0% 0% 0.01% 0.18% 0.13% 0.10%
0% X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
X X X 0% 0% X 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X X X
X 0% 0% 0% 0% 0% X
X X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% 0% 0% 0%
Q->K 1.2% 0% 0% 0% 0% 0.05% 0.14%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
X X 0% 0% X 0% X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
T->A 0% 0% 0% 0% 0% 1.6% 0.10%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
T->A 0% 1.1% 1.6% 0.01% 0% 0.38% 0.49%
0% X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
X X X 0% 0% X X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X X X
X 0% 0% 0% 0% 0% X
X X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
F->S 0% 0% 0% 0.01% 4.2% 2.9% 4.9%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% X
X X 0% 0% X 0% X
0% 0% 0% 0% 0% 0% 0%
F->S 2.3% 0.99% 0% 0.08% 0% 0.15% 0.03%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
X X X 0% 0% X X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% X X
X 0% 0% 0% 0% 0% X
X X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% X 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% X 0% X 0% 0%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% X
X X 0% 0% 0% 0% X
X X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
D->G 0% 1.2% 0% 0.01% 0.44% 0.26% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% X 0% X 0% 0%
X X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% X
D->Q X X 100% 100% 98% 100% X
D->Q X X 100% X 100% 99% X
D->Q 100% X 100% 100% 95% 100% X
D->Q X X 100% 100% X 100% 100%
0% 0% 0% 0% 0% 0% 0%
D->E 0% 0% 0% 0% 0% 0.02% 1.5%
sP915548 1a S->R 0% X 0% 0% X 0.21% 1.1%
sP824545 1a 0% 0% 0% 0% 0% 0% 0%
sP495677 1a 0% 0% 0% 0% 0% 0% 0%
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1a X X 0% 0% 0% 0% 0%
sP643870 1a 0% 0% 0% 0% 0% 0% 0%
sP799685 1a 0% X 0% 0% 0% 0% 0%
sP641886 1a S->R 0.36% 0% 0% 0% 0% 0.20% 1.5%
sP759580 1a S->R 0% 0% 0% 0% 0% 0.16% 1.2%
sP528652 1b 0% X 0% 0% 0% 0% 0%
sP883026 1b 0% 0% 0% 0% 0% 0% 0%
sP841485 1b 0% 0% 0% 0% 0% 0% 0%
sP791266 1b S->R 0% 0% 0% 0% 0% 0.26% 1.8%
sP598047 1b S->R X X X 0% 0% 0.95% 3.1%
sP455229 1b 0% 0% X 0% 0% 0% 0%
sP371169 2a X X 0% 0% 0% 0% X
sP681788 2b S->R 99% 100% 100% 100% 100% 100% 100%
sP093793 2b S->R 100% 99% 100% 100% X 100% 99%
sP181675 2b S->R 100% 100% 100% 100% 100% 100% 100%
sP546783 3a 0% X 0% 0% X 0% X
sP575531 3a X X 0% 0% 0% 0% X
sP800022 3a X X 0% 0% 0% 0% X
sP510486 3a 0% X 0% 0% 0% 0% X
sP260631 3a 0% 0% 0% 0% X 0% 0%
sP731482 4a 0% 0% 0% 0% 0% 0% 0%
sP312482 4d 0% 0% 0% 0% 0% 0% 0%
S->G 0% X 0% 0.07% 0% 1.7% 1.2%
S->N 1.9% 0% 0% 0% 0% 0% 0.65%
0% 0% 0% 0% 0% 0% 0%
S->G,N 1.3% 2.9% 1.6% 1.1% 2.7% 0.84% 10%
0% 0% 0% 0% 0% 0% 0%
S->G X X 1.1% 0% 0% 1.3% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
S->G,N 0% 0% 0% 0.22% 0% 1.8% 3.3%
S->N 0% 0% 0% 0% 0% 0.32% 4.0%
S->N 0% X 0% 0.18% 0% 0.86% 3.3%
S->N 1.6% 0.84% 0% 0.04% 0% 0.11% 1.5%
S->N 2.9% 6.5% 9.9% 3.1% 3.2% 4.7% 7.0%
S->N 1.1% 0.69% 0% 0% 0% 0.26% 2.8%
S->N X X X 0% 0% 1.9% 5.4%
0% 0% X 0% 0% 0% 0%
X X 0% 0% 0% 0% X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% X
X X 0% 0% 0% 0% X
S->K X X 100% 100% X X X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
S->T 99% 99% 100% 100% 99% 99% 99%
S->T 100% 100% 100% 100% 100% 99% 100%
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0% 1.0% 100% X Missing DataMajority variantMinor variant>99% wild type
sP915548 1a Q->R 0% 0% 0.11% 0% 1.9% 0%
sP824545 1a Q->R 1.9% 0% 0% 0.03% 0.55% 1.0% 0.03%
sP495677 1a 0% 0% 0% 0% 0% 0% 0%
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1a Q->R 0% 0% 0.03% 0% 4.1% 1.6%
sP643870 1a 0% 0% 0% 0% 0% 0% X
sP799685 1a Q->R 0% 0% 0.82% X 12% 0%
sP641886 1a 0% 0% 0% 0% 0% 0% 0%
sP759580 1a 0% 0% 0% 0% 0% 0% 0%
sP528652 1b Q->R 80% 100% 100% 100% 100% 99% 100%
sP883026 1b Q->R 99% 100% 100% 100% 100% 100% 100%
sP841485 1b Q->R 100% 100% 100% 100% 100% 99% 100%
sP791266 1b Q->R 99% 100% 100% 100% 100% 87% 100%
sP598047 1b Q->R 100% 100% X 100% 100% 97% 100%
sP455229 1b Q->R 100% 100% X 100% X 100% 100%
sP371169 2a X X X 0% 0% 0% 0%
sP681788 2b 0% 0% 0% 0% 0% 0% 0%
sP093793 2b 0% 0% 0% 0% X 0% 0%
sP181675 2b 0% 0% X 0% 0% 0% 0%
sP546783 3a X X 0% 0% 0% X X
sP575531 3a 0% X X 0% 0% 0% X
sP800022 3a 0% X 0% 0% 0% 0% X
sP510486 3a 0% X 0% 0% 0% 0% X
sP260631 3a 0% 0% 0% 0% X 0% 0%
sP731482 4a Q->R 100% 100% 100% 0% 100% 100% 100%
sP312482 4d Q->R 100% 100% 100% 100% 100% 98% 99%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% X
0% X 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
L->M 1.7% 0.36% 0% 0% 0.05% 0.05% 0.73%
0% 0% X 0% 0% 0% 0%
L->M 0% 0% X 0% X 0% 1.4%
L->M X X 100% X 100% 99%
L->M 0.12% 0.10% 0% 0.77% 0.83% 3.5% 1.3%
L->M 99% 100% 100% 100% X 99% 98%
L->M 0.16% 0% X 0% 0% 1.1% 0.25%
X X 0% 0% 0% X X
0% X X 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
L->M 99% 100% 98% X 100% 100% 100%
L->M 97% 100% 100% 99% 100% 99% 99%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Y->H 1.1% 0% 0% 0% 0% 0.14% 0.02%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Y->H 0% 0% 0% 0% 1.2% 1.4%
Y->H 1.6% 0% 0% 0.01% 0% 0.17% X
Y->H 0% 0% 0% 0% 2.9% 0%
0% 0% 0% 0% 0% 0% 0%
Y->H 1.0% 0% 0% 0% 0% 0.02% 0%
X X 0% 0% 0% 0% 0%
Y->H 99% 100% 100% 99% 99% 98% 100%
Y->H 0.95% 0% 0% 0.23% 0.23% 1.4% 0.10%
Y->H 0% 0.47% 0% 0.03% 0.10% 1.5% 0.15%
Y->H 0% X 0% 3.7% 1.1% 0.04%
Y->S 0% 0% X 0% 0% 0% 2.2%
X X X 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
Y->S 0.70% 0% 0% 0% X 0.02% 1.6%
Y->S 0.35% 0% X 0% 0.23% 0.06% 1.1%
X X 0% 0% X X X
0% X X 0% 0% 0% X
0% X 0% 0% 0% 0% X
Y->H 11% 0% 0.88% 0% 0.60% X
0% X 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
sP915548 1a 0% X 0% 0% 0% 0% 0%
sP824545 1a S->T 2.7% 7.7% 0% 0% 0% 0.07% 0.06%
sP495677 1a 0% 0% 0% 0% 0% 0% 0%
sP237998 1a 0% 0% 0% 0% 0% 0% 0%
sP256432 1a 0% 0% 0% 0% 0% 0% 0%
sP104509 1a X X X 0% 0% 0% 0%
sP643870 1a 0% 0% 0% 0% 0% 0% 0%
sP799685 1a 0% X 0% 0% 0% 0% 0%
sP641886 1a 0% 0% 0% 0% 0% 0% 0%
sP759580 1a 0% 0% 0% 0% 0% 0% 0%
sP528652 1b 0% X 0% 0% 0% 0% 0%
sP883026 1b 0% 0% 0% 0% 0% 0% 0%
sP841485 1b 0% 0% 0% 0% 0% 0% 0%
sP791266 1b 0% 0% 0% 0% 0% 0% 0%
sP598047 1b 0% X X 0% 0% 0% 0%
sP455229 1b 0% 0% X 0% 0% 0% X
sP371169 2a X X X 0% 0% 0% 0%
sP681788 2b 0% 0% X 0% 0% 0% 0%
sP093793 2b 0% 0% X 0% X 0% 0%
sP181675 2b 0% 0% X 0% 0% 0% 0%
sP546783 3a 0% X 0% 0% 0% 0% X
sP575531 3a X 0% 0% 0% 0% 0% X
sP800022 3a 0% X 0% 0% 0% 0% X
sP510486 3a 0% X 0% 0% 0% 0% X
sP260631 3a 0% X 0% 0% X 0% 0%
sP731482 4a 0% 0% 0% 0% 0% 0% 0%
sP312482 4d 0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
C->N 0.4% 0% 0% 0% 100% 0.1% 0.1%
C->N 0% 0% 0% 0% 0.1% 1.3% 0.2%
C->N 60% 100% 99% 100% 100% 100%
C->N 99% 99% 100% 100% 100% 97% 99%
C->N 0% 0% 0% 0% 0.1% 1.3% 0.2%
C->N 0.8% 0% 0% 0% 0.1% 1.6% 0.3%
C->N 100% X X 100% 100% 92% 99%
C->N 0% 0% X 0.3% 0% 9.5% 0%
X X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
0% 0% X 0% X 0% 0%
0% 0% X 0% 0% 0% 0%
0% X 0% 0% 0% X X
X 0% 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% X 0% 0% 0% 0% X
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% X 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
X X X 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% X 0% X
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% 0% 0% 0% 0% 0% 0%
0% X X 0% 0% 0% 0%
0% 0% X 0% 0% 0% 0%
0% X X 0% 0% X 0%
0% 0% X 0% 0% 0% 0%
0% 0% X 0% X 0% 0%
0% 0% X 0% 0% 0% 0%
X X 0% 0% X 0% X
X X 0% 0% 0% 0% 0%
X X 0% 0% 0% 0% 0%
0% X 0% 0% 0% 0% 0%
L->S 0% 0% 0% 0% 0% 0% 1.2%
0% 0% 0% X 0% 0% 0%
0% X 0% 0% 0% 0% 0%
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